Complete Guide to Peptides for Fat Loss Muscle Building and Longevity - Dr. Kyle Gillett MD

Half a Million Views and a Very Different Kind of Peptide Video

This conversation between Derek from More Plates More Dates and Dr. Kyle Gillett is one of the most information-dense peptide videos on YouTube. At nearly half a million views, it has clearly found its audience, and that audience is people who want the detailed science, more than the surface-level talking points. Dr. Gillett is an obesity medicine and hormone specialist who thinks carefully about peptide applications, and Derek asks the kind of follow-up questions that force real specificity.

Fair warning: this is not a beginner-friendly video. If you are brand new to peptides, start with a foundational overview first. This conversation assumes you already know the basics and are ready for a deeper discussion about how specific peptides fit into fat loss, muscle building, and longevity protocols.

The Fat Loss Peptide Hierarchy

Dr. Gillett organizes fat loss peptides into a hierarchy based on evidence strength and clinical utility. At the top are the GLP-1 receptor agonists, specifically semaglutide and tirzepatide. He is straightforward about this: if your primary goal is fat loss and you qualify for GLP-1 therapy, nothing else in the peptide world comes close in terms of magnitude of effect and quality of evidence.

Below the GLP-1 drugs, he places growth hormone secretagogues, particularly CJC-1295 and Ipamorelin. These do not produce the dramatic appetite suppression and weight loss of GLP-1 drugs, but they improve body composition by increasing growth hormone output, which promotes fat oxidation and lean mass preservation. The effect on fat loss is more subtle and more dependent on other variables (diet, exercise, sleep) than GLP-1 therapy.

Dr. Gillett makes an important distinction between fat loss and weight loss. GLP-1 drugs produce weight loss, meaning the number on the scale drops significantly. Growth hormone secretagogues produce body recomposition, meaning fat mass decreases and lean mass increases, but the scale may not move as dramatically. For someone who is significantly overweight, the GLP-1 approach is usually more appropriate. For someone who is close to their goal weight but wants to improve body composition (less fat, more muscle), the GH secretagogue approach may be more relevant.

He also discusses Tesamorelin, a GH-releasing hormone analog that is FDA-approved for HIV-associated lipodystrophy. Tesamorelin reduces visceral fat (the deep abdominal fat that wraps around organs) more effectively than other GH secretagogues in clinical studies. For people whose primary concern is visceral fat specifically, Tesamorelin has the strongest evidence.

Muscle Building: Peptides vs. Anabolics

Derek pushes Dr. Gillett on whether peptides can genuinely build muscle, and the answer is nuanced. Growth hormone secretagogues increase GH and IGF-1 levels, both of which support muscle protein synthesis. But the muscle-building effect from peptide-induced GH elevation is much smaller than what you get from anabolic steroids. Dr. Gillett estimates the effect at roughly 10-15% improvement in muscle protein synthesis above baseline, compared to 200-300% or more from supraphysiological testosterone.

Where peptides add value for muscle building is in recovery and injury prevention rather than raw hypertrophy. Better GH output means faster recovery between training sessions, improved tendon and connective tissue integrity, and enhanced sleep quality (GH is released primarily during deep sleep, and GH secretagogues can improve sleep architecture). All of these factors contribute to better long-term muscle development even if the acute hypertrophic effect is modest.

BPC-157 and TB-500 earn a mention in the muscle building context not for direct hypertrophy, but for keeping you training consistently. The number one killer of long-term muscle development is injury. A torn rotator cuff, a strained lower back, or chronic tendinitis can sideline someone for weeks or months. Healing peptides that prevent or accelerate recovery from these injuries have a compound effect on muscle building over years that is easy to underestimate.

The Longevity Angle

This section of the conversation is where Dr. Gillett is most cautious and most interesting. Longevity-focused peptide use is inherently more speculative than using peptides for a specific therapeutic goal, because the outcome (living longer and healthier) takes decades to measure and is influenced by hundreds of variables.

His primary concern with growth hormone peptides in a longevity context mirrors Peter Attia's: the IGF-1 question. Growth hormone peptides elevate IGF-1, and chronically elevated IGF-1 is associated with increased cancer risk in population studies. The centenarian data consistently shows that people who live to 100+ tend to have lower IGF-1 levels, not higher ones. This creates a tension for anyone using GH peptides with longevity as a goal.

Dr. Gillett's practical approach is dose-dependent. He suggests that modest GH peptide dosing that brings IGF-1 into the mid-normal range (around 150-200 ng/mL) is probably net positive for most people, because the benefits to sleep, recovery, body composition, and bone density at that level likely outweigh the oncological risk. But pushing IGF-1 above 250-300 ng/mL chronically is a different calculation, and one he does not recommend for patients whose primary goal is longevity.

For pure longevity applications, he is more enthusiastic about BPC-157 and GHK-Cu. Both have anti-inflammatory and tissue-protective effects without the IGF-1 elevation concerns. BPC-157's effects on gut health and systemic inflammation address two of the major drivers of age-related disease. GHK-Cu's gene expression modulation touches on antioxidant defense, DNA repair, and tissue remodeling pathways that are all relevant to aging. Neither compound raises the cancer signaling concerns that come with GH elevation.

Stacking Peptides with GLP-1 Therapy

This is a topic that few people discuss, and Dr. Gillett provides useful guidance. For patients on semaglutide or tirzepatide who are losing weight, the main risk is lean mass loss. Adding a growth hormone secretagogue like CJC-1295/Ipamorelin during GLP-1 therapy can help preserve lean mass during rapid weight loss. The GH elevation supports muscle protein synthesis and shifts the ratio of weight loss more toward fat and away from muscle.

He also suggests BPC-157 as a companion to GLP-1 therapy for patients experiencing GI side effects. The nausea, constipation, and occasional gastroparesis that some people experience on semaglutide may be mitigated by BPC-157's gastroprotective and gut motility effects. This is an off-label application with no clinical trial data to support it, but the mechanistic rationale is sound and Dr. Gillett has observed positive results anecdotally in his practice.

Dosing Principles and Common Mistakes

Dr. Gillett outlines several dosing principles that apply across the peptide space. First, start low and titrate up. The optimal dose for any peptide is the lowest dose that produces the desired effect. More is not better, especially with compounds that affect hormonal axes.

Second, cycle when appropriate. Growth hormone secretagogues may benefit from cycling (8-12 weeks on, 4 weeks off) to prevent receptor desensitization. Healing peptides like BPC-157 and TB-500 are typically used for defined treatment courses (4-12 weeks) rather than indefinitely.

Third, test your IGF-1 levels if you are using any growth hormone peptide. This is non-negotiable. You need to know where your IGF-1 sits at baseline and where it goes during treatment. If it climbs above 250 ng/mL, reduce the dose.

Common mistakes he sees include stacking too many peptides without knowing how each one affects you individually, using high doses from day one instead of titrating, running growth hormone peptides without monitoring IGF-1, and treating peptide protocols as permanent rather than as tools for specific goals with defined timelines.

Your Action Plan

Define your primary goal before selecting any peptide. Fat loss, muscle building, injury recovery, and longevity are different goals that call for different compounds. Do not try to optimize for everything at once.

If fat loss is the priority and you have significant weight to lose (BMI 30+), GLP-1 therapy should be your first conversation with a physician. Peptides like CJC-1295/Ipamorelin can complement that therapy by preserving lean mass, but they are not substitutes for the GLP-1 effect.

If body recomposition is the goal (you are near your target weight but want less fat and more muscle), growth hormone secretagogues combined with structured resistance training and high protein intake is a reasonable protocol. Monitor IGF-1 levels and keep them in the mid-normal range.

If injury recovery is driving your interest, BPC-157 and TB-500 as a combination, potentially with GHK-Cu for remodeling, is the standard starting point. Use them for a defined treatment course with objective outcome tracking.

Whatever you choose, work with a physician who understands the compounds, get baseline and follow-up labs, and evaluate your results based on data rather than feelings. The peptide space has enormous potential, but only when used with the same rigor you would apply to any other medical intervention.

One more point from Dr. Gillett that deserves emphasis: the biggest variable in peptide outcomes is not the peptide itself. It is the lifestyle context in which the peptide is used. A growth hormone secretagogue in someone who sleeps six hours a night, trains sporadically, and eats poorly will produce mediocre results. The same peptide in someone who consistently sleeps 7-8 hours, trains with progressive overload four times per week, and eats 1 gram of protein per pound of lean body mass will produce dramatically better outcomes. The peptide amplifies whatever your lifestyle is already doing. If your lifestyle is not optimized, fix that first.

Derek and Dr. Gillett also briefly discuss the economic reality of peptide therapy. A thorough protocol with GH secretagogues, healing peptides, and regular lab monitoring can easily cost $400-$800 per month when sourced from legitimate compounding pharmacies. That is a significant expense that needs to be weighed against the realistic expected benefit. For someone recovering from a specific injury, a defined 8-12 week protocol may be worth the investment. For someone using peptides as general optimization without a specific target, the cost-benefit math is less favorable, and the money might be better spent on a personal trainer, a sleep specialist, or better food.